RA PHARMACEUTICALS, INC. Research and Development Expense
RA PHARMACEUTICALS, INC. reported Research and Development Expense of $82.64 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-02-27
- RA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-12-31 was $26.20M, a 70.63% increase year-over-year.
- RA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-09-30 was $23.24M, a 73.79% increase year-over-year.
- RA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-06-30 was $17.91M, a 45.58% increase year-over-year.
- RA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-03-31 was $15.28M, a 13.94% increase year-over-year.
- RA PHARMACEUTICALS, INC. research and development expense for fiscal 2019 was $82.64M, a 51.78% increase from fiscal 2018.
- RA PHARMACEUTICALS, INC. research and development expense for fiscal 2018 was $54.45M, a 20.33% increase from fiscal 2017.
- RA PHARMACEUTICALS, INC. research and development expense for fiscal 2017 was $45.25M, a 62.03% increase from fiscal 2016.
- RA PHARMACEUTICALS, INC. research and development expense for fiscal 2016 was $27.93M, a 83.53% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2019-12-31 | $26.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $49.45M derived: sum of 2 quarters · filed 2020-02-27 | $67.36M derived: sum of 3 quarters · filed 2020-02-27 | $82.64M 10-K · filed 2020-02-27 |
| 2019-09-30 | $23.24M 10-Q · filed 2019-11-07 | $41.16M derived: sum of 2 quarters · filed 2019-11-07 | $56.44M 10-Q · filed 2019-11-07 | $71.80M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $17.91M 10-Q · filed 2019-08-07 | $33.20M 10-Q · filed 2019-08-07 | $48.55M derived: sum of 3 quarters · filed 2020-02-27 | $61.93M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $15.28M 10-Q · filed 2019-05-09 | $30.64M derived: sum of 2 quarters · filed 2020-02-27 | $44.01M derived: sum of 3 quarters · filed 2020-02-27 | $56.32M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $15.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $28.73M derived: sum of 2 quarters · filed 2020-02-27 | $41.04M derived: sum of 3 quarters · filed 2020-02-27 | $54.45M 10-K · filed 2020-02-27 |
| 2018-09-30 | $13.38M 10-Q · filed 2019-11-07 | $25.68M derived: sum of 2 quarters · filed 2019-11-07 | $39.09M 10-Q · filed 2019-11-07 | $51.74M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $12.30M 10-Q · filed 2019-08-07 | $25.72M 10-Q · filed 2019-08-07 | $38.36M derived: sum of 3 quarters · filed 2019-08-07 | $51.49M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $13.41M 10-Q · filed 2019-05-09 | $26.06M derived: sum of 2 quarters · filed 2019-05-09 | $39.19M derived: sum of 3 quarters · filed 2019-05-09 | $49.65M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $25.77M derived: sum of 2 quarters · filed 2019-03-07 | $36.24M derived: sum of 3 quarters · filed 2019-03-07 | $45.25M 10-K · filed 2019-03-07 |
| 2017-09-30 | $13.13M 10-Q · filed 2018-11-07 | $23.59M derived: sum of 2 quarters · filed 2018-11-07 | $32.61M 10-Q · filed 2018-11-07 | $41.99M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $10.46M 10-Q · filed 2018-08-08 | $19.48M 10-Q · filed 2018-08-08 | $28.86M derived: sum of 3 quarters · filed 2018-08-08 | $35.94M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $9.01M 10-Q · filed 2018-05-09 | $18.40M derived: sum of 2 quarters · filed 2018-05-09 | $25.48M derived: sum of 3 quarters · filed 2018-05-09 | $31.98M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $9.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $16.47M derived: sum of 2 quarters · filed 2018-03-14 | $22.97M derived: sum of 3 quarters · filed 2018-03-14 | $27.93M 10-K · filed 2018-03-14 |
| 2016-09-30 | $7.08M 10-Q · filed 2017-11-09 | $13.58M derived: sum of 2 quarters · filed 2017-11-09 | $18.54M 10-Q · filed 2017-11-09 | $23.16M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $6.50M 10-Q · filed 2017-08-09 | $11.46M 10-Q · filed 2017-08-09 | $16.09M derived: sum of 3 quarters · filed 2018-03-14 | $20.11M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $4.96M 10-Q · filed 2017-05-11 | $9.58M derived: sum of 2 quarters · filed 2018-03-14 | $13.61M derived: sum of 3 quarters · filed 2018-03-14 | |
| 2015-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $8.65M derived: sum of 2 quarters · filed 2018-03-14 | $15.22M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $4.03M 10-Q · filed 2016-11-29 | $10.59M 10-Q · filed 2016-11-29 | ||
| 2014-12-31 | $10.02M 10-K · filed 2017-03-06 |